Comparative Pharmacology
Head-to-head clinical analysis: PEPCID COMPLETE versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID COMPLETE versus PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER.
PEPCID COMPLETE vs PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famotidine competitively inhibits histamine at H2-receptors of gastric parietal cells, reducing gastric acid secretion. Calcium carbonate and magnesium hydroxide act as antacids to neutralize existing gastric acid.
Competitive histamine H2-receptor antagonist; inhibits gastric acid secretion by blocking H2 receptors on parietal cells.
One tablet (famotidine 10mg, calcium carbonate 800mg, magnesium hydroxide 165mg) orally once daily, taken 30 minutes before a meal that causes heartburn.
20 mg intravenously every 12 hours; or 40 mg intravenously once daily. For Zollinger-Ellison syndrome, initial dose 20 mg intravenously every 6 hours; adjust based on acid output.
None Documented
None Documented
2.5-3.5 hours (prolonged to 12-20 hours in severe renal impairment, CrCl <10 mL/min).
2.5–3.5 hours in normal renal function; prolonged to 6–8 hours in moderate renal impairment (CrCl <50 mL/min) and up to 20 hours in severe renal failure (CrCl <10 mL/min)
Renal: 65-70% (famotidine unchanged); fecal: 30-35% (as metabolites). Biliary elimination is minimal (<5%).
Renal (65–70% unchanged via tubular secretion and glomerular filtration); biliary/fecal (minor, <10%)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist